Page 21 - மரபியல் ஒன்றுபட்டது கிஂக்டம் கூட்டமைப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Oxford-AstraZeneca vaccine effective against B.1.1.7 SARS-CoV-2 variant The coronavirus disease (COVID-19) pandemic continues to spread globally, with new variants emerging. One of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants is the B.1.1.7 or U.K. variant. It is still unclear if the developed vaccines can protect against new emerging variants. Now, researchers at the COVID-19 Genomics United Kingdom Consortium, the AMPHEUS Project, and the Oxford COVID-19 Vaccine Trial Group released the results of their exploratory analysis of a randomized controlled trial of the ChAdOx1 nCoV-19 (AZD1222) vaccine against the SARS-CoV-2 variant of concern 202012/01 or the B.1.1.7 variant. Published in

United kingdomUnited statesAngela betsaidab laguipoGenomics united kingdom consortiumVaccine trial groupDrug administrationAngela betsaidaUnited kingdom consortiumTrial groupEmergency use authorizationSars cov 2Corona virusCoronavirus disease covid 19Severe acute respiratorySevere acute respiratory syndromeஒன்றுபட்டது கிஂக்டம்